Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Phase 3 Trial (Japan, jRCT2080223401)
jRCT2080223401Phase 3Completed
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pembrolizumab in cancer. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223401.